What does the future hold for Adamis Pharmaceuticals Corporation (NASDAQ:ADMP)? Raymond James analyst Elliot Wilbur is out today with a bullish note on the specialty biopharmaceutical company, after the latter announced that it has submitted an IND to test naloxone in human patients using Symject, presumably as a reaction to the worsening opioid crisis.
Story Continues
